Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis

Abstract Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in desperate need of a protection against SARS-CoV-2 infection. Methods In this study, Euroimmun semi-quantitative Anti-SARS-CoV-2 IgG for detection of humoral response and ELISpot assays for detection of SARS-C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mosche Pompsch, Neslinur Fisenkci, Peter A. Horn, Markus Kraemer, Monika Lindemann
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Ocrelizumab B-cell depleted patients SARS-CoV2 vaccination Comirnaty® T-cell mediated response Lack of antibody response Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/d35be905bf80480d9a2dc2d9f19feff1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d35be905bf80480d9a2dc2d9f19feff1
record_format	dspace
spelling	oai:doaj.org-article:d35be905bf80480d9a2dc2d9f19feff12021-11-28T12:06:31ZEvidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis10.1186/s42466-021-00158-52524-3489https://doaj.org/article/d35be905bf80480d9a2dc2d9f19feff12021-11-01T00:00:00Zhttps://doi.org/10.1186/s42466-021-00158-5https://doaj.org/toc/2524-3489Abstract Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in desperate need of a protection against SARS-CoV-2 infection. Methods In this study, Euroimmun semi-quantitative Anti-SARS-CoV-2 IgG for detection of humoral response and ELISpot assays for detection of SARS-CoV-2-specific T-cell-response were used in 10 ocrelizumab-treated patients with multiple sclerosis twice vaccinated with Comirnaty® mRNA vaccine. This data was compared with a control group of 20 age- and sex-matched healthy volunteers, who had all previously received a full SARS-CoV-2 mRNA vaccination with Comirnaty® or Spikevax®. Results While all subjects in the control group had high humoral response to the vaccination, in B-cell-depleted individuals a significantly reduced antibody response to vaccination against SARS-CoV-2 was observed. SARS-CoV-2 specific T-cell-response, however, did not differ significantly between both cohorts. Conclusions T-cell-mediated response to Comirnaty® vaccination is observable despite attenuated humoral response in B-cell-depleted patients. This might enable partial protection against COVID-19. Trial registration Retrospectively registered.Mosche PompschNeslinur FisenkciPeter A. HornMarkus KraemerMonika LindemannBMCarticleOcrelizumabB-cell depleted patientsSARS-CoV2 vaccinationComirnaty®T-cell mediated responseLack of antibody responseNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeurological Research and Practice, Vol 3, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ocrelizumab B-cell depleted patients SARS-CoV2 vaccination Comirnaty® T-cell mediated response Lack of antibody response Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Ocrelizumab B-cell depleted patients SARS-CoV2 vaccination Comirnaty® T-cell mediated response Lack of antibody response Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Mosche Pompsch Neslinur Fisenkci Peter A. Horn Markus Kraemer Monika Lindemann Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
description	Abstract Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in desperate need of a protection against SARS-CoV-2 infection. Methods In this study, Euroimmun semi-quantitative Anti-SARS-CoV-2 IgG for detection of humoral response and ELISpot assays for detection of SARS-CoV-2-specific T-cell-response were used in 10 ocrelizumab-treated patients with multiple sclerosis twice vaccinated with Comirnaty® mRNA vaccine. This data was compared with a control group of 20 age- and sex-matched healthy volunteers, who had all previously received a full SARS-CoV-2 mRNA vaccination with Comirnaty® or Spikevax®. Results While all subjects in the control group had high humoral response to the vaccination, in B-cell-depleted individuals a significantly reduced antibody response to vaccination against SARS-CoV-2 was observed. SARS-CoV-2 specific T-cell-response, however, did not differ significantly between both cohorts. Conclusions T-cell-mediated response to Comirnaty® vaccination is observable despite attenuated humoral response in B-cell-depleted patients. This might enable partial protection against COVID-19. Trial registration Retrospectively registered.
format	article
author	Mosche Pompsch Neslinur Fisenkci Peter A. Horn Markus Kraemer Monika Lindemann
author_facet	Mosche Pompsch Neslinur Fisenkci Peter A. Horn Markus Kraemer Monika Lindemann
author_sort	Mosche Pompsch
title	Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
title_short	Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
title_full	Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
title_fullStr	Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
title_full_unstemmed	Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
title_sort	evidence of extensive cellular immune response after sars-cov-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
publisher	BMC
publishDate	2021
url	https://doaj.org/article/d35be905bf80480d9a2dc2d9f19feff1
work_keys_str_mv	AT moschepompsch evidenceofextensivecellularimmuneresponseaftersarscov2vaccinationinocrelizumabtreatedpatientswithmultiplesclerosis AT neslinurfisenkci evidenceofextensivecellularimmuneresponseaftersarscov2vaccinationinocrelizumabtreatedpatientswithmultiplesclerosis AT peterahorn evidenceofextensivecellularimmuneresponseaftersarscov2vaccinationinocrelizumabtreatedpatientswithmultiplesclerosis AT markuskraemer evidenceofextensivecellularimmuneresponseaftersarscov2vaccinationinocrelizumabtreatedpatientswithmultiplesclerosis AT monikalindemann evidenceofextensivecellularimmuneresponseaftersarscov2vaccinationinocrelizumabtreatedpatientswithmultiplesclerosis
_version_	1718408226892939264

Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis

Ejemplares similares